CareDx CDNA shares ended the last trading session 11.2% higher at $24.91. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

CareDx (CDNA) reported $86.58 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 32%. EPS of $0.18 for the same period compares to -$0.17 a year ago.

Through laboratory techniques that track quantities of mRNA, scientists can identify which genes are “turned on” and which are “turned off” in an organism’s tissue at a given time, as ...

Norgen’s microScript microRNA cDNA Synthesis Kit is a complete, ready-to-use kit for reverse transcription of microRNA from either whole RNA or enriched microRNA preparations. The kit includes ...

The new MessageBOOSTER cDNA Synthesis from Cell Lysates kit eliminates these difficulties by enabling RNA amplification and cDNA synthesis directly from cell lysates, without the need to purify ...

Currently, the analyst consensus on CareDx is a Moderate Buy with an average price target of $27.83. Based on CareDx’s latest earnings release for the quarter ending December 31, the company reported ...

Prudential Financial Inc. boosted its position in shares of CareDx, Inc (NASDAQ:CDNA – Free Report) by 58.5% in the 4th quarter, according to the company in its most recent 13F filing with the ...